<DOC>
	<DOCNO>NCT00316745</DOCNO>
	<brief_summary>This randomized phase III study compare safety efficacy two sequence arm advance colorectal cancer : irinotecan S-1 ( IRIS ) follow oxaliplatin contain regimen ( arm A ) , l-leucovorin ( l-LV ) , 5-FU oxaliplatin ( mFOLFOX6 ) follow irinotecan contain regimen ( arm B ) .</brief_summary>
	<brief_title>IRIS Followed mFOLFOX6 Reverse Sequence Advanced Colorectal Cancer</brief_title>
	<detailed_description>A multicenter randomize open-label controlled phase III study conduct patient inoperable advanced metastatic colorectal cancer receive previous chemotherapy . Usefulness IRIS mFOLFOX6 regimens 1st-line therapy colorectal cancer evaluate PFS , MST , incidence severity adverse event</detailed_description>
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<mesh_term>Irinotecan</mesh_term>
	<mesh_term>Camptothecin</mesh_term>
	<mesh_term>Fluorouracil</mesh_term>
	<mesh_term>Levoleucovorin</mesh_term>
	<criteria>1 . Histological diagnosis colorectal cancer . 2） Age : 18 75 year . 3） No prior chemotherapy 4） ECOG Performance Status 0 2 5 ) A life expectancy least 3 month 6 ) Adequate function major organ ( bone marrow , heart , lung , liver etc. ) . WBC ≧3,500/mm3 Neutrophil ≧2,000/mm3 . Hb ≧10.0 g/dl . Platelet count ≧100,000/mm3 . AST ALT ≦2.5 time upper limit normal ( exclude liver metastasis ) . TBil ≦1.5 mg/dl . Creatinine ≦1.5 mg/ dl . 7 ) .Patients must ability understand willingness sign write inform contact document . 1 . Patients receive blood transfusion , blood derivative granulocytecolony stimulate factor within 7days prior enter study . 2 . Patients oral intake 3 . Patients receive Flucytosine treatment 4 . Patients severe pleural effusion ascites . 5 . Patients brown brain metastasis 6 . Patients diarrhea 4 time per day 7 . Patients active gastrointestinal bleeding . 8 . Patients intestinal obstruction 9 . Patients active infection . 10 . Patients serious pulmonary disease ( interstitial pneumonia , pulmonary fibrosis , pulmonary emphysema ) 11 . Patients serious complication ( intestinal paralysis , intestinal obstruction , interstitial pneumonia pulmonary fibrosis , uncontrolled diabetes mellitus , heart failure , renal failure , hepatic failure ) . 12 . Patients significant cardiac disease . 13 . Patients active multiple cancer . 14 . Patients neuropathy ≥ grade 2 15 . Patients pregnant , childbearing potential , breastfeed . 16 . Patients severe mental disorder . 17 . Patients history serious allergic reaction . 18 . Judged ineligible protocol investigation .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>October 2007</verification_date>
	<keyword>irinotecan</keyword>
	<keyword>S-1</keyword>
	<keyword>Oxaliplatin</keyword>
	<keyword>l-leucovorin</keyword>
	<keyword>Fluorouracil</keyword>
	<keyword>Metastatic colorectal cancer</keyword>
	<keyword>phase III</keyword>
</DOC>